| Price | $1.48 |
| Year Range | $1.24 – $5.62 |
| Market Cap | $90M |
| Industry | Biotechnology |
What Is Aldeyra Therapeutics’s AI Stock Analysis?
Aldeyra Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Aldeyra Therapeutics’s momentum in near-real time.
Aldeyra Therapeutics (ALDX) has an AltIndex AI Score of 61/100, currently a Buy signal. The AI Score distills Aldeyra Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Aldeyra Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Aldeyra Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving ALDX’s AI Score?
Fundamentals
Revenue for the last quarter was $0. This is equal to the revenue of the quarter before it, showing stability. Also, this is equal to the revenue of the same quarter last year, indicating consistency. Net income for the last quarter was $-5.5M. This represents a decrease of 57.86% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of -44.20%, suggesting positive year-over-year growth. Ebitda for the last quarter was $-5.4M. This represents a decrease of 84.40% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of -41.74%, suggesting positive year-over-year growth.
See Aldeyra Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $1.48. This represents a decrease of 4.52% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 73.38%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $1.50, which is lower than the previous SMA10 of $1.51. This suggests a potential downward trend in price movement. The RSI is 25.6, indicating a potentially oversold (bullish) condition.
See the full technical analysis and price prediction.
Alternative data
The business outlook among employees at Aldeyra Therapeutics is very high (an estimate of 100% of employees have a positive outlook), a positive sign. Aldeyra Therapeutics has an estimate of 4,000 visitors to their webpage. The number of visitors is down by -33% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore Aldeyra Therapeutics’s job postings, web traffic and app downloads.
Sentiment & social
Aldeyra Therapeutics has 470 followers on their Twitter page. The number of followers is down by -1% in the last couple of months, indicating a loss in interest in the company.
Track Aldeyra Therapeutics’s market sentiment.
Frequently Asked Questions: Aldeyra Therapeutics AI Stock Analysis
Aldeyra Therapeutics's AltIndex AI Score is 61/100, currently a Buy signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Aldeyra Therapeutics a Buy (61/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Aldeyra Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the ALDX AI Score or sign up to read the full thesis.
